Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Transient receptor potential cation channel subfamily A member 1 opener
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetic Neuropathies; Tobacco Use Disorder; Deglutition Disorders; Hypertension; Stomach Neoplasms; Arthralgia; Arthritis; Asthma; Back Pain; Bronchitis; Burns; Bursitis; Common Cold; Contusions; Cough; Eczema; Headache; Hemorrhoids; Herpes Labialis; Insect Bites and Stings; Muscle Cramp; Myalgia; Nasal Obstruction; Oral Ulcer; Osteoarthritis; Pain; Pharyngitis; Pruritus; Sprains and Strains; Sunburn; Tendinopathy; Wounds and Injuries
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Synaptic vesicular amine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL; OTHER
THERAPEUTIC INDICATION: Tourette Syndrome; Movement Disorders; Huntington Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Back Pain; Chronic Pain; Diabetic Neuropathies; Hallux Valgus; Joint Diseases; Low Back Pain; Neoplasms; Neuralgia; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Voltage-gated L-type calcium channel blocker
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: CARDIOVASCULAR; OTHER
THERAPEUTIC INDICATION: Scoliosis; Hypertension; Hypertension, Malignant; Stroke; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Alpha-1a adrenergic receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Prostatitis; Kidney Calculi; Prostatic Neoplasms, Castration-Resistant; Prostatic Hyperplasia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Pain; Epilepsy; Lennox Gastaut Syndrome; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adenosine A2a receptor agonist
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Anemia, Sickle Cell; Retinal Artery Occlusion; Coronary Disease; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Amyotrophic Lateral Sclerosis; Kidney Diseases; Alcoholism; Brain Neoplasms; Fibromyalgia; Glioma; Migraine Disorders; Neuralgia; Neuralgia, Postherpetic; Osteoarthritis; Anxiety; Dementia; Depressive Disorder; Diabetic Neuropathies; Epilepsies, Partial; Erythromelalgia; Schizophrenia; Status Epilepticus; Epilepsy; Seizures
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M2 antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Urinary Incontinence; Urinary Bladder, Overactive; Urinary Incontinence, Urge
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Peroxisome proliferator-activated receptor alpha agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Alcoholism; Cholestasis; Medulloblastoma; Hypertriglyceridemia; Diabetes Mellitus, Type 2; Hypercholesterolemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: IV (INFUSION)
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Plasma Cell; Myelodysplastic Syndromes; Amyloidosis, Familial; Breast Neoplasms; Hodgkin Disease; Leukemia; Leukemia, Hairy Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Small Cell Lung Carcinoma; Waldenstrom Macroglobulinemia; Immunoblastic Lymphadenopathy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Arthritis; Back Pain; Bursitis; Contusions; Muscle Cramp; Myalgia; Pain; Sprains and Strains; Tendinopathy; Wounds and Injuries
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; OTHER
THERAPEUTIC INDICATION: Infections; Acquired Immunodeficiency Syndrome; Friedreich Ataxia; HIV; HIV Infections; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: C-X-C chemokine receptor type 4 partial agonist
ROUTE OF ADMINISTRATION: SUBCUTANEOUS
STATUS: Approved
THERAPEUTIC AREA: CANCER
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 1; Diabetic Foot; End Stage Liver Disease; Graft vs Host Disease; Kidney Diseases; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Thalassemia; beta-Thalassemia; Anemia, Sickle Cell; Fanconi Anemia; Gliosarcoma; Granulomatous Disease, Chronic; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Lymphopenia; Pancreatic Neoplasms; Scleroderma, Systemic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Coronary Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Multiple Myeloma; Nasopharyngeal Neoplasms; Genital Neoplasms, Female; Nausea; Neoplasms; Postoperative Nausea and Vomiting
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thrombopoietin receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Myelodysplastic Syndromes; Anemia, Aplastic; Hepatitis C, Chronic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anemia; Liver Cirrhosis; Osteosarcoma; Blood Platelet Disorders; Fanconi Anemia; Graft vs Host Disease; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Diseases; Lymphoma; Myelodysplastic Syndromes; Wiskott-Aldrich Syndrome; Anemia, Aplastic; Hepatitis C; Hepatitis C, Chronic; Neoplasms; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Hemorrhage
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Intestinal Obstruction; Kidney Diseases; Liver Diseases; Opioid-Related Disorders; Gastroparesis; Pancreatitis; Constipation; Ileus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glutathione reductase
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Leukemia; Myelodysplastic Syndromes; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Autonomic Dysreflexia; Urinary Bladder, Neurogenic; Urinary Bladder, Overactive; Polyuria; Urinary Incontinence
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cataract; Conjunctivitis, Bacterial; Eye Infections
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rhinitis, Allergic, Seasonal; Conjunctivitis, Allergic; Dermatitis; Rhinitis, Allergic, Perennial
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Osteoporosis, Postmenopausal; Endometrial Hyperplasia; Menopause; Osteoporosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vanilloid receptor opener
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM
THERAPEUTIC INDICATION: Cough; Pruritus; Stroke; Facial Pain; HIV Infections; Hypertension, Pulmonary; Myofascial Pain Syndromes; Nausea; Neuralgia, Postherpetic; Neuroma; Tennis Elbow; Vomiting; Angina, Stable; Breast Neoplasms; Common Cold; Diabetic Neuropathies; Head and Neck Neoplasms; Herpes Zoster; Osteoarthritis, Knee; Peripheral Nervous System Diseases; Arthralgia; Arthritis; Back Pain; Bursitis; Contusions; Muscle Cramp; Myalgia; Neuralgia; Osteoarthritis; Pain; Sprains and Strains; Tendinopathy
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Hepatocellular; Colorectal Neoplasms; Corneal Neovascularization; Glioblastoma; Lymphoma; Psoriasis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chondrosarcoma; Dermatofibrosarcoma; Fallopian Tube Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Gliosarcoma; Hemangiosarcoma; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphedema; Macular Degeneration; Melanoma; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Osteosarcoma; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma; Solitary Fibrous Tumors; Stomach Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Sarcoma; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: SUBLINGUAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Psychotic Disorders; Stuttering; Bipolar Disorder; Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: SUBLINGUAL; TRANSDERMAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Bipolar Disorder; Psychotic Disorders; Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Asthma; Heart Diseases; Acute Coronary Syndrome; Anemia, Sickle Cell; Atrial Fibrillation; Coronary Disease; Influenza, Human; Myocardial Infarction; Pneumonia; Renal Insufficiency, Chronic; ST Elevation Myocardial Infarction; Severe Acute Respiratory Syndrome; Thrombosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Potassium-transporting ATPase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Barrett Esophagus; Esophagitis, Peptic; Duodenal Ulcer; Esophagitis; Gastroesophageal Reflux; Heartburn; Peptic Ulcer; Stomach Ulcer
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Influenza, Human; Metabolic Syndrome; Renal Insufficiency; Breast Neoplasms; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypercholesterolemia; Hyperlipidemias; Ischemic Stroke; Lipid Metabolism Disorders; Cardiovascular Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Gamma-amino-N-butyrate transaminase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER; PEDIATRICS
THERAPEUTIC INDICATION: Tourette Syndrome; Alcoholism; Amphetamine-Related Disorders; Cocaine-Related Disorders; Obesity; Tuberous Sclerosis; Epilepsy; Epilepsy, Complex Partial; Spasms, Infantile
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Liver Diseases; Stress Disorders, Post-Traumatic; Bipolar Disorder; Psychotic Disorders; Schizophrenia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vasopressin V2 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Kidney Calculi; Carcinoma; Kidney Diseases; Renal Insufficiency, Chronic; Dyspnea; Edema, Cardiac; Inappropriate ADH Syndrome; Liver Cirrhosis; Polycystic Kidney, Autosomal Dominant; Cardiovascular Diseases; Heart Failure; Hyponatremia; Polycystic Kidney Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ferriprotoporphyrin IX inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: HIV Infections; Neoplasms; Schistosomiasis haematobia; Fever; Malaria, Falciparum; Malaria, Vivax; Malaria